Myasthenia gravis (Latin Wikipedia)

Analysis of information sources in references of the Wikipedia article "Myasthenia gravis" in Latin language version.

refsWebsite

Global rank Latin rank

4^th place

12^th place

low place

low place

2^nd place

35^th place

doi.org

Howard Jr. J. F., Utsugisawa K., Benatar M., Murai H., Barohn R. J., Illa I., Jacob S., Vissing J., Burns T. M., et al. (Dec 2017). "Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study". The lancet. Neurology 16 (12): 976-86 doi:10.1016/S1474-4422(17)30369-1

nih.gov

pubmed.ncbi.nlm.nih.gov

Trouth A. J., Dabi A., et al. (2012). "Myasthenia gravis: a review". Autoimmune diseases
Howard Jr. J. F., Utsugisawa K., Benatar M., Murai H., Barohn R. J., Illa I., Jacob S., Vissing J., Burns T. M., et al. (Dec 2017). "Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study". The lancet. Neurology 16 (12): 976-86 doi:10.1016/S1474-4422(17)30369-1

ncbi.nlm.nih.gov

McGrogan A., Sneddon S., de Vries C. S. (2010). "The incidence of myasthenia gravis: a systematic literature review". Neuroepidemiology 34 (3): 171-83

wikipedia.org

en.wikipedia.org

Howard Jr. J. F., Utsugisawa K., Benatar M., Murai H., Barohn R. J., Illa I., Jacob S., Vissing J., Burns T. M., et al. (Dec 2017). "Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study". The lancet. Neurology 16 (12): 976-86 doi:10.1016/S1474-4422(17)30369-1